The 20 analysts offering 12-month price forecasts for Fate Therapeutics Inc have a median target of 64.50, with a high estimate of 115.00 and a low estimate of 28.00. The median estimate represents a +208.61% increase from the last price of 20.90.
The current consensus among 22 polled investment analysts is to Buy stock in Fate Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.88
Reporting Date Feb 27
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.